Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)Seeking Alpha • 01/11/21
Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health CanadaBusiness Wire • 12/28/20
Vertex Pharmaceuticals Enters New Partnership With RNA Expert Skyhawk TherapeuticsThe Motley Fool • 12/22/20
Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare MutationsBusiness Wire • 12/21/20
Vertex Pharmaceuticals (VRTX) Stock Moves -0.08%: What You Should KnowZacks Investment Research • 12/18/20